Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel

Urology

Volumn 78, Issue 5, 2011, Pages 1125-1130

  Gebbia, Vittorio ^a   Serretta, Vincenzo ^a   Borsellino, Nicolò ^b   Valerio, Maria Rosaria ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Buccheri La Ferla Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; GONADORELIN AGONIST; METHOTREXATE; METOCLOPRAMIDE; NARCOTIC ANALGESIC AGENT; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANALGESIA; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE ADENOCARCINOMA; CASTRATION RESISTANT PROSTATE CANCER; CYSTITIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MCGILL PAIN QUESTIONNAIRE; METASTASIS; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE ADENOCARCINOMA; SALVAGE THERAPY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADENOCARCINOMA; ADMINISTRATION, METRONOMIC; ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; HUMANS; MALE; METHOTREXATE; PROSTATIC NEOPLASMS; SALVAGE THERAPY; TAXOIDS; TREATMENT FAILURE;

EID: 80455143255     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2011.08.010     Document Type: Article

References (29)

1. D.P. Petrylak, C.M. Tangen, and M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 35 2004 1513 1520 (Pubitemid 39315318)
2. I.F. Tannock, R. De Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone in advanced prostate cancer N Engl J Med 35 2004 502 1512
3. B.A. Kamen, E. Rubin, and J. Aisner High-time chemotherapy or high time for low dose J Clin Oncol 18 2000 2935 2937 (Pubitemid 30644116)
4. R.S. Kerbel, and B.A. Kamen The anti-angiogenic basis of metronomic chemotherapy Nat Rev Cancer 4 2004 423 4362
5. T. Browder, C.E. Butterfield, and B.M. Krling Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer Cancer Res 60 2000 1878 1886 (Pubitemid 30207647)
6. G. Bocci, K.C. Nicolaou, and R.S. Kerbel Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs Cancer Res 62 2002 6938 6943 (Pubitemid 35424084)
7. T. Nelius, K. Rinard, and S. Filleur Oral/metronomic cyclophosphamide- based chemotherapy as option for patients with castration-refractory prostate cancerReview of the literature Cancer Treat Rev 2011 [Epub ahead of print]
8. M. Colleoni, A. Rocca, and M.T. Sandri Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels Ann Oncol 13 2002 73 80 (Pubitemid 34436728)
9. C. Kyriakou, K. Thomson, and S. D'Sa Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma Br J Haematol 129 2005 763 770 (Pubitemid 40904526)
10. O. Mir, J. Domont, and A. Cioffi Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma Eur J Cancer 47 2011 515 519
11. M. Findlay, G. von Minckwitz, and A. Wardley Effective oral chemotherapy for breast cancer: pillars of strength Ann Oncol 19 2008 212 222 (Pubitemid 351201700)
12. V. Serretta, V. Altieri, and G. Morgia Oral chemotherapy in hormone-refractory prostate carcinoma patients unwilling to be admitted to hospital Urol Int 83 4 2008 452 457
13. National Cancer Institute Common Termination Criteria for Adverse Events, version 3.0 2003 National Cancer Institute Washington, DC
14. G.J. Bubley, M. Carducci, and W. Dahut Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol 17 1999 3461 3467 (Pubitemid 29517916)
15. P. Therasse, S.G. Arbuck, E.A. Eisenhauer National Cancer Institute of Canada New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States J Natl Cancer Inst 92 2000 205 216
16. D.C. Turk, R.H. Dworkin, and L.B. Burke Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations Pain 125 2006 208 215 (Pubitemid 44711972)
17. W.M. Hryniuk, and M. Goodyear The calculation of received dose intensity J Clin Oncol 8 1990 1935 1937
18. N. Mottet, J. Bellmunt, and M. Bolla EAU guidelines on prostate cancer part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer Eur Urol 59 2011 572 583
19. S.J. Hotte, and F. Saad Current management of castrate-resistant prostate cancer Curr Oncol 17 Suppl 2 2010 S72 S79
20. F. Saad, S.J. Hotte Canadian Urologic Oncology Group; (CUOG) and the Canadian Urological Association (CUA) Guidelines for the management of castrate-resistant prostate cancer Can Urol Assoc J 4 2010 380 384
21. J. Michels, T. Montemurro, and N. Murray First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? Cancer 106 2006 1041 1046
22. W.K. Oh, J. Manola, and V. Babcic Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes Urology 67 2006 1235 1240 (Pubitemid 43818095)
23. D.R. Berthold, G.R. Pond, and R. de Wit Survival and psa response of patients in the tax 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa Ann Oncol 19 2008 1749 1753
24. J.E. Rosenberg, V.K. Weinberg, and W.K. Kelly Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone Cancer 110 2007 556 563 (Pubitemid 47106144)
25. J.S. De Bono, C.J. Logothetis, and A. Molina Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 26 364 2011 1995 2005
26. J.S. de Bono, S. Oudard, and M. Ozguroglu Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 5114
27. S. Hirata, T. Matsubara, and R. Saura Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate Arthritis Rheum 32 1989 1065 1073 (Pubitemid 19237859)
28. T. Nelius, T. Klatte, and W. de Riese Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy Med Oncol 7 2009 363 367
29. G.P. Murphy Review of phase II hormone refractory prostate cancer trials Urology 54 6A Suppl 1999 19 21